UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: (Date of earliest event reported): November 16, 1999
Huntingdon Life Sciences Group plc ("Huntingdon")
---------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
England
---------------------------------------------------------------------
(State or other jurisdiction of incorporation)
1-10173 N/A
- ------------------------------- --------------------------------
(Commission File Number) (I.R.S. Employer Identification Number)
Huntingdon Research Centre, Woolley Road, Alconbury, Huntingdon,
Cambs, PE 17 5HS, England
---------------------------------------------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code: +44 (1480) 892000
- ---------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5 OTHER EVENTS
On November 16, 1999, Huntingdon Life Sciences Group plc (the "Company") issued
a press release, attached as Exhibit No. 99.1 hereto, announcing that:
99.1 the Company had filed Form 10-Q in respect of the quarter ended September
30, 1999.
<PAGE>
Item 7 EXHIBITS
(c) Exhibits
Exhibit No. Description
99.1 Press release issued by Huntingdon Life Sciences Group plc
on November 16, 1999 relating to Form 10-Q in respect of the
quarter ended September 30, 1999.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
HUNTINGDON LIFE SCIENCES GROUP PLC
/s/ Susan G. Hide
By: Susan G Hide
GROUP COMPANY SECRETARY
Dated: November 16, 1999
<PAGE>
EXHIBIT INDEX
Exhibit No. Description
99.1 Press release issued by Huntingdon Life Sciences Group plc
on November 16, 1999 relating to Form 10-Q in respect of the
quarter ended September 30, 1999.
PRESS RELEASE Huntingdon Life Sciences Group plc
("Huntingdon") (NYSE/SEAQ:HTD)
Woolley Road, Alconbury, Huntingdon
Cambs PE17 5HS, England
For Further Information:
Richard A. Michaelson
Phone: UK: +44 (0) 1480 892194
US: (201) 525-1819
e-mail: [email protected]
IMMEDIATE RELEASE
November 16, 1999
HUNTINGDON FILES THIRD QUARTER 10-Q
Huntingdon, England, November 16, 1999 - Huntingdon Life Sciences Group, plc
("the Company")(NYSE:HTD) announced that it has filed its Form 10-Q with the
United States Securities and Exchange Commission. A printed copy of the Form
10-Q is available on request from the registered office at Woolley Road,
Alconbury, Huntingdon, Cambs PE17 5HS, England
The Financial Statements reported in that filing have been prepared in
accordance with US GAAP, under which pension costs, holiday pay and taxation are
accounted for differently than under UK GAAP. This has resulted in Net Income
for the third quarter in the 10-Q being (pound)1.0 million greater than that
reported in the Company's UK Third Quarter Results announced on October 27,
1999. This change has no impact on cashflow, and simply reflects the different
Generally Accepted Accounting Principles of both countries. In future the
Company will provide financial information under both standards in its earnings
releases.
In addition the Company has reclassified its (pound)22.5 million bank debt
outstanding as short term debt due to the term of the loan expiring on August
31, 2000, as reported in the August 1998 Prospectus relating to the
Subscription, Placing and Open Offer. This reclassification of the debt does not
affect the Company's net assets as reported in the Third Quarter Results, but
does increase current liabilities from (pound)17.9 million to (pound)40.4
million, while decreasing long term liabilities from (pound)52.7 million to
(pound)30.2 million.
Huntingdon Life Sciences Group plc is one of the world's leading CROs providing
product development services to the pharmaceutical, agrochemical and
biotechnology industries. Huntingdon brings leading technology and capability to
support its clients in non-clinical safety testing of new compounds in early
stage development and assessment. Huntingdon operates research facilities in the
United Kingdom (Huntingdon and Eye, England) and the United States (The
Princeton Research Centre, New Jersey).
This announcement contains statements that may be forward-looking as defined by
the USA's Private Litigation Reform Act of 1995. These statements are based
largely on Huntingdon's expectations and are subject to a number of risks and
uncertainties, certain of which are beyond Huntingdon's control, as more fully
described in Huntingdon's Form 20-F as filed with the US Securities and Exchange
Commission.
* * * end * * *
